This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Mavacoxib 30mg|
|Indication||Treatment of pain and inflammation associated with degenerative joint disease in dogs.|
|Contraindications||Do not use in animals with gastrointestinal ulceration or bleeding, or where there is evidence of a haemorrhagic disorder. Do not use in pregnant, breeding or lactating animals, in cases of impaired liver or kidney function, heart insufficiency, or if there is known hypersensitivity to sulfonamides. Do not use in dehydrated dogs. The safety of mavacoxib in dogs younger than 12 months or less than 5 kg, or in pregnant, breeding or lactating dogs has not been established, therefore Trocoxil is not recommended for use in these classes of dog.|
|Actions||Mavacoxib is a cyclooxygenase-2 (COX-2) nonsteroidal anti-inflammatory drug (NSAID) which possesses analgesic and anti-inflammatory properties. Mavacoxib is an NSAID of the coxib class. Mavacoxib is a 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide. It is a diaryl-substituted pyrazole.|
|Precautions||Care should be taken to avoid treatment of animals that might not tolerate prolonged NSAID exposure. Mavacoxib exhibits an extended plasma half-life (up to and over 80 days) due to its low rate of elimination and bioaccumulative effects. This corresponds to a duration of effect of one to two months after administration of the second dose (and following doses). A maximum treatment of 6.5 months' continuous therapy is recommended so as to manage plasma levels of mavacoxib in animals which exhibit reduced elimination.Animals should undergo a thorough clinical examination before commencing treatment with Trocoxil, and appropriate laboratory tests to monitor haematological status and clinical chemistry are recommended. Animals with evidence of impaired renal or hepatic function or with evidence of a protein or blood losing enteropathy are not suitable for treatment with Trocoxil.Other NSAIDs or glucocorticoids should not be used concurrently or within at least one month of the last administration of Trocoxil. Pretreatment with other anti-inflammatory substances may result in additional or increased adverse effects. To avoid such effects when Trocoxil is to be administered in replacement of another NSAID, ensure an appropriate treatment free period of at least 24 hours before administering the first dose of Trocoxil. The treatment free period should take into account the pharmacology of the medicines used previously. Should another NSAID be administered after Trocoxil treatment, a treatment free period of at least one month should be ensured to avoid adverse effects.Avoid use in dehydrated, hypovolaemic or hypotensive animals, as there is a potential risk of increased renal toxicity. Ensure appropriate hydration and haemodynamic status when animals receiving mavacoxib undergo anaesthesia and/or surgical procedures or develop conditions which may result in dehydration or compromised haemodynamic status. Patients with underlying renal disease may experience exacerbation or decompensation of their renal disease while on NSAID therapy.Harmful if swallowed. May irritate the eyes. Do not swallow. Avoid contact with eyes. Wash hands after use. Ingestion of mavacoxib can be harmful to children, and prolonged gastrointestinal and pharmacological effects may be observed after accidental ingestion. To avoid accidental ingestion, administer the tablet to the dog immediately after removal from the blister package.First Aid If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131 126.Disposal Dispose of empty container by wrapping with paper and putting in garbage.|
|Dosage and Administration||This is not a daily treatment. Administer orally with food at a dose rate of 2 mg/kg bodyweight. The initial dose should be repeated 14 days later. Thereafter, the dosing interval is one month. A treatment should not exceed seven consecutive doses (6.5 months).As the bioavailability of mavacoxib when given with food is nearly twice that in fasted dogs, treatment should be given immediately before or during the animal's main meal. Care should be taken to ensure that the tablet is ingested.|
|Storage||Store below 30°C (room temperature).|
|MSDS (external link)||Trocoxil Chewable 30mg MSDS|
|Label (external link)||Trocoxil Chewable 30mg Label|
|Manufacturer||Zoetis Australia Pty Ltd|